This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Neoadjuvant Carboplatin, Weekly Abraxane and Trastuzumab in HER2+ Breast Cancer

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified July 2014 by William Sikov, Brown University.
Recruitment status was:  Active, not recruiting
Yale University
Information provided by (Responsible Party):
William Sikov, Brown University Identifier:
First received: February 6, 2008
Last updated: July 15, 2014
Last verified: July 2014
Q3week carboplatin with weekly abraxane and trastuzumab as neoadjuvant therapy in resectable and unresectable HER2+ (stage IIa-IIIb) breast cancer

Condition Intervention Phase
Breast Cancer Drug: Carboplatin Drug: nab-paclitaxel Drug: trastuzumab Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: BrUOG-BR-211B q3week Carboplatin With Weekly Abraxane and Trastuzumab As Neoadjuvant Therapy in Resectable and Unresectable HER2+ (Stage IIa-IIIb) Breast Cancer

Resource links provided by NLM:

Further study details as provided by William Sikov, Brown University:

Primary Outcome Measures:
  • To determine the clinical and pathologic response rates, particularly the pCR/near pCR rate, observed following treatment with q3week carboplatin, weekly Abraxane and weekly trastuzumab in resectable and unresectable LABC; [ Time Frame: 1 year ]

Secondary Outcome Measures:
  • Assess toxicities of regimen during treatment, including grade >2 neurotoxicity the incidence of subclinical and clinical cardiac toxicity [ Time Frame: 1 year ]

Enrollment: 60
Study Start Date: February 2008
Estimated Study Completion Date: December 2014
Primary Completion Date: August 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Phase II
Drug: Carboplatin, Abraxane, Trastuzumab
Drug: Carboplatin
Carboplatin AUC 6
Other Name: Abraxane (nab-paclitaxel), Herceptin (trastuzumab)
Drug: nab-paclitaxel
Abraxane 100 mg/m2
Other Name: Abraxane (nab-paclitaxel)
Drug: trastuzumab
trastuzumab 2 mg/kg
Other Name: Herceptin (trastuzumab)

Detailed Description:
Our goal is to develop an induction chemotherapy regimen that will have a pCR rate above 50% in HER2+ patients without exposing patients to the toxicity of an anthracycline-based regimen. A minimum of 60 evaluable patients will be accrued to the study. We are assuming an observed pCR (or near pCR) rate of 70%. Assuming no more than 10% of patients will be inevaluable for the primary endpoint (pCR), we will have at least 54 evaluable patients. With this number, we will have 90% power, with a 1-sided alpha error of 0.05, to demonstrate a pCR rate exceeding 50% for our novel regimen.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically documented adenocarcinoma of the breast
  • ANC > 1000 cells
  • Female; age > 18; Zubrod PS 0-1
  • Platelets > 100,000
  • Stage IIA-IIIB disease
  • Total bilirubin < or = ULN
  • No evidence of metastatic disease Not pregnant or lactating
  • No prior systemic therapy for this breast cancer
  • Serum Creatinine < 1.5 mg/dl or Creat Cl > 30 ml/min
  • Serum ALT < 2.5 x ULN
  • ER, PR and HER2 status required
  • LVEF (MUGA/echo)WNL
  • No baseline > 2 neuropathy
  • Hemoglobin > 9.0 gm/dl
  • HER2+, defined by IHC 3+ or FISH ratio > 2.0
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00617942

United States, California
City of Hope
Duarte, California, United States, 91010
United States, Connecticut
Yale Smilow Cancer Center
New Haven, Connecticut, United States, 06437
United States, Rhode Island
Women and Infants Hospital
Providence, Rhode Island, United States, 02903
Roger Williams Medical Center
Providence, Rhode Island, United States, 02908
Rhode Island and The Miriam Hospital
Providence, Rhode Island, United States, 02912
Sponsors and Collaborators
William Sikov
Yale University
Principal Investigator: William Sikov, MD Brown University
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: William Sikov, Principle Investigator, Brown University Identifier: NCT00617942     History of Changes
Other Study ID Numbers: BrUOG-BR-211B
Study First Received: February 6, 2008
Last Updated: July 15, 2014

Keywords provided by William Sikov, Brown University:
Breast Cancer

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Albumin-Bound Paclitaxel
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action processed this record on July 25, 2017